

OncoMethylome Sciences to Collaborate with GlaxoSmithKline Biologicals for Personalized Cancer Treatment

Liege (Belgium) – November 26, 2007, 8:00am CET – OncoMethylome Sciences announced today that it has entered into a collaboration with GlaxoSmithKline (GSK) Biologicals. The goal of the collaboration is to develop DNA methylation biomarkers for use in the personalization of cancer treatment with certain immunotherapeutics in development by GSK Biologicals.

“We look forward to using our high-throughput platform to efficiently test our portfolio of methylation biomarkers on clinical samples provided by GSK Biologicals. We are pleased that GSK Biologicals has chosen OncoMethylome for this collaboration” commented Dr. Jim DiGuseppi, Chief Technology Officer of OncoMethylome.

The collaboration is supported by a Wallonia (BioWin) research grant that was announced in April of this year. Further financial details of the agreement were not disclosed.

To download this press release as a PDF, click here: [Press Release PDF](#)

About Methylation and Methylation Biomarkers

Methylation is a natural control mechanism that regulates gene expression in DNA. Abnormal methylation of certain genes can silence gene expression and is associated with cancer development and response to cancer therapy. Genes whose methylation is linked to cancer are often called methylation biomarkers. Methylation biomarkers intended for use in companion diagnostics are associated with response to cancer drug therapy. OncoMethylome owns proprietary technology that is highly sensitive and capable detecting methylation biomarkers, and is also very suitable for testing these markers in a high-throughput manner on clinical samples.

About OncoMethylome Sciences

OncoMethylome Sciences (Euronext Brussels: ONCOB; Euronext Amsterdam: ONCOA) is a molecular diagnostics company developing gene methylation tests to assist physicians in effectively detecting and treating cancer. Specifically, the company's tests are designed to help the physician (i) accurately detect cancer in early stages of cancer development, (ii) predict a patient's response to drug therapy, and (iii) predict the likelihood of cancer recurrence.

OncoMethylome boasts a broad product development pipeline consisting of ten products and a solid partnering record. The company collaborates with leading international molecular oncology research centers, such as The Johns Hopkins University, and has a number of commercial and collaborative partnerships with Veridex LLC, a Johnson & Johnson company, Schering-Plough Corp., Millipore Corporation's BioScience Division, and EXACT Sciences Corp. OncoMethylome's products are based on methylation technology invented by Johns Hopkins University (USA).

Established in January 2003, OncoMethylome has offices in Liege and Leuven (Belgium), in Durham, NC (USA), and in Amsterdam (the Netherlands).

For more information please contact:

Lucija Turcinov

Tel. +32-479-801-902

Lucija.Turcinov@oncomethylome.com

or visit: www.oncomethylome.com